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ORIGINAL ARTICLE
Background/Aims: The present study was performed to determine the effects of the ethyl acetate extract of
Cudrania tricuspidata (EACT) on interleukin (IL)-1β-stimulated receptor activator of NF-κB ligand (RANKL)-
mediated osteoclast differentiation.
Methods: Bone marrow cells were harvested from 6-week-old male imprinting control region mice, and the
differentiation of osteoclasts from these cells was evaluated by tartrate-resistant acid phosphatase and
resorption pit formation assay. Phosphorylated extracellular signal regulated kinase (p-ERK), phosphorylated
p38, phosphorylated c-Jun amino-terminal kinase, NF-κB (p65), IκBα, c-Fos, and nuclear factor of activated T-
cells c1 (NFATc1) expression was examined by immunoblotting and quantitative reverse transcription-polymerase
chain reaction. 
Results: EACT inhibits IL-1β-stimulated RANKL-mediated osteoclast differentiation. EACT also inhibits IL-1β-
stimulated RANKL-mediated phosphorylation of ERK 1/2, p38 mitogen activated protein kinase, and expression
of c-Fos and NFATc1.  
Conclusions: These results suggest that EACT may be involved in the inhibition of bone loss by preventing
osteoclast formation and may be used to manage bone destruction in inflammatory diseases, such as rheumatoid
arthritis. (Korean J Intern Med 2010;25:93-100)
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INTRODUCTION
Bone homeostasis is maintained by ensuring a balance
between bone-resorbing osteoclasts and bone-forming
osteoblasts. Many factors closely regulate bone resorption
and bone formation in vivo to maintain bone homeostasis
[1]. Bone erosion due to excessive osteoclast formation can
occur in association with estrogen deficiency and increases
in inflammatory diseases, such as rheumatoid arthritis
(RA) and periodontal disease [2]. Most therapeutic drugs
currently in use to treat osteoporosis inhibit osteoclast
formation and thus bone resorption. Consequently, it is
necessary to develop effective therapeutic drugs capable of
improving the quality and quantity of bone.
Osteoclasts are the cells primarily responsible for bone
resorption, and differentiation of these cells is regulated
by multiple processes through differential gene expression.
Osteotropic agents, including interleukin (IL)-1, IL-6, IL-
11, IL-15, IL-17, tumour necrosis factor (TNF)-α,
prostaglandin E2, and parathyroid hormone, cause bone
loss by increasing osteoclast formation [1,3]. Receptor
activator of NF-κB ligand (RANKL), an essential osteo-
clastogenic cytokine, recruits TNF receptor-associated
factor (TRAF) proteins through binding to its receptor,RANK, on the surface of osteoclast precursors. TRAFs
activate various signaling pathways, including c-Src,
PI3-kinase/Akt, and mitogen activated protein kinase
(MAPK) [4]. Several transcription factors, including c-
Fos, nuclear factor of activated T-cells (NFAT) c1, PU1,
and microphthalmia-associated transcription factor, are
activated by RANKL and are important for osteoclast
differentiation [5]. In particular, expression of c-Fos
induced by RANKL plays an essential role in the initiation
of osteoclast differentiation. c-Fos is responsible for the
expression of NFATc1 during RANKL-mediated osteoclast
differentiation [6,7].   
Cudrania tricuspidata (CT) is a deciduous tree distributed
over South Korea, China, and Japan, the cortex and root
bark of which are used as a traditional medicine for
curing inflammation and tumors [8]. Several reports
have suggested various effects of CT extract, including
antioxidant activity [9], inhibitory effects on nitric oxide
synthase [10], and inhibitory effects on the proliferation
of inflammatory immune cells and tumor cells [11,12].
However, there have been no investigations of the effects
of ethyl acetate extract of CT (EACT) on the differentiation
of osteoclasts, which play a crucial role in the pathogenesis
of bone loss in several diseases, including RA. 
We examined the inhibitory mechanism of EACT on IL-
1β-stimulated RANKL-mediated osteoclast differentiation.
Intracellular signaling factors were evaluated to define the
mechanisms underlying the effects of EACT on osteoclast
differentiation. We report here that EACT inhibits IL-1β-
stimulated RANKL-mediated osteoclast differentiation by
inhibiting extracellular signal regulated kinase (ERK) 1/2,
p38 MAPK, c-Fos, and NFATc1 activation.
METHODS
Reagents and antibodies
Recombinant human IL-1β was purchased from R&D
Systems (Minneapolis, MN, USA), and human soluble
RANKL and macrophage colony stimulating factor (M-
CSF) were purchased from PeproTech Inc. (Rocky Hill,
NJ, USA). Monoclonal antibodies against ERK 1/2,
phosphorylated ERK (p-ERK) 1/2, c-Jun amino-terminal
kinase (JNK), phosphorylated JNK (p-JNK), p38,
phosphorylated p38 (p-p38), NF-κB (p65), IκBα, and β-
actin were purchased from Cell Signaling Technology
(Beverly, MA, USA). Antibodies against c-FOS and NFATc1
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Fetal bovine serum was obtained from
Gibco BRL Life Technologies (Grand Island, NY, USA). 
Preparation of crude extract of C. tricuspidata
C. tricuspidata was collected from Jiri Mountain,  Korea,
and plant material was identified by an authority at the
Rheumatology Laboratory and Research Center for
Pulmonary Diseases, Chonbuk National University Medical
School, Jeonju, Korea. Fresh stem bark was removed with a
sickle and dried in a dark, well-ventilated room.
Air-dried stem bark (1 kg) was cut into pieces and
extracted with 50% methanol at room temperature for
several days. The methanol extract of CT was evaporated
and partitioned consecutively with n-hexane, benzene,
trichloromethane, ethyl acetate, and n-butanol as described
previously [9]. The ethyl acetate fraction was used in this
study after drying. 
Isolation of osteoclast precursors and
osteoclastogenesis
Osteoclast precursors were prepared as described
previously with some modifications [13]. Briefly, bone
marrow cells were obtained from the tibia and femur of 5-
week-old male imprinting control region (ICR) mice. Red
blood cells were removed in red blood cells lysis buffer
(Sigma, St. Louis, MO, USA). Following centrifugation,
bone marrow cells were suspended in α-MEM (Welgene,
Seoul, Korea) containing 10% fetal bovine serum (Gibco
BRL) and antibiotics and were cultured for 1 day in the
presence of M-CSF (10 ng/mL). After 1 day, nonadherent
cells were seeded on 10-cm culture dishes and cultured for
3 days in the presence of M-CSF (30 ng/mL); newly
adherent cells were used as bone marrow cells. For the
osteoclast differentiation assay, bone marrow macrophages
prepared from bone marrow cells were cultured for 3 days
with M-CSF (30 ng/mL) and RANKL (50 ng/mL). Bone
marrow macrophages were cultured for 4 days with M-
CSF (30 ng/mL) and RANKL (50 ng/mL) in the presence
or absence of IL-1β(1 ng/mL) or EACT (100 µg/mL).
Cell viability analysis
Cell viability was determined using a CCK-8 kit
(Dojindo Laboratories, Kumamoto, Japan) according to
the manufacturer’s instructions. Briefly, 2-(2-methoxy-4-
nitrophenyl)-3-(4-nitropenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium (CCK-8) was reduced by dehydrogenases in
cells to yield an orange-colored product (formazan) [14].
The amount of formazan dye generated by dehydrogenases
94 The Korean Journal of Internal Medicine Vol. 25, No. 1, March 2010Lee EG, et al. Cudrania tricuspidata inhibits osteoclast differentiation    95
A B
A B
IL-1β - / EACT -
IL-1β - / EACT +
Figure 2. Inhibition of IL-1β-stimulated, RANKL-mediated resorption area formation by EACT. (A) Osteoclast precursors were
cultured with M-CSF (30 ng/mL) and RANKL (50 ng/mL) for 2 wk in the presence or absence of IL-1β (1.0 ng/mL) or EACT (100
µg/mL) on OAAS plate. (B) The area of resorption pit (arrow) was calculated.
Error bars indicate the standard deviation of the mean (n = 3).
IL, interleukin; RANKL, receptor activator of NF-κB ligand; TRAP, tartrate-resistant acid phosphatase; EACT, ethyl acetate extract of
Cudrania tricuspidata; M-CSF, macrophage colony stimulating factor.
ap < 0.05 vs. no IL-1β and EACT.
bp < 0.05 vs. no IL-1β and EACT.
cp < 0.05 vs. IL-1β without EACT.
Figure 1. Inhibition of IL-1β-stimulated, RANKL-mediated TRAP (+) cell formation by EACT. (A) Osteoclast precursors were cultured
with M-CSF (30 ng/mL) and RANKL (50 ng/mL) for 3 days in the presence or absence of IL-1β (1.0 ng/mL) or EACT (100 µg/mL).
Cells were fixed in 10% formalin, permeabilized with 0.1% Triton X-100, and stained with TRAP solution. (B) TRAP+ cells containing
five or more nuclei were counted as multinucleated osteoclasts (arrows).
Error bars indicate the standard deviation of the mean (n = 3).
IL, interleukin; RANKL, receptor activator of NF-κB ligand; TRAP, tartrate-resistant acid phosphatase; EACT, ethyl acetate extract of
Cudrania tricuspidata; M-CSF, macrophage colony stimulating factor.
ap < 0.05 vs. no IL-1β and EACT.
bp < 0.05 vs. no IL-1β and EACT.
cp < 0.05 vs. IL-1β without EACT.
IL-1β - / EACT - IL-1β + / EACT -
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IL-1β + / EACT +in cells was directly proportional to the number of living
cells. Bone marrow cells from the 5-week-old male ICR
mice (1 × 104 cells per well in complete α-MEM media in
96-well plates) were cultured in 200 µL medium per well
with M-CSF (30 ng/mL) and RANKL (50 ng/mL) or IL-1β
(1 ng/mL) in the presence or absence of EACT (100 µg/
mL) for 3 days. CCK-8 (20 µL) was added to each well of
the plate, and the cells were incubated for 3 hours.
Absorbance was measured at 450 nm using a microplate
reader.
Immunoblotting
Cells were lysed in lysis buffer containing 50 mM Tris-
Cl, 150 mM NaCl, 5 mM EDTA 1% Triton X-100, 1 mM
sodium fluoride, 1 mM sodium vanadate, 1% deoxycholate,
and protease inhibitors. The protein concentration was
determined using Bio-Rad protein assay reagent (Bio-Rad
Laboratories, CA, USA). Samples (50 µg) were prepared
with four volumes of 0.5 M Tris buffer (pH 6.8) containing
4% SDS, 20% glycerol, and 0.05% bromophenol blue at
95˚C for 5 min. SDS-PAGE was performed in 10% slab
gels, and the proteins were transferred onto nitrocellulose
membranes. The membranes were washed in blocking
buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 5% fat-
free milk) for 60 min at room temperature with shaking
and then washed with TBST (TBS, 0.01% Tween 20).
Primary antibodies against ERK 1/2, p-ERK 1/2, p38, p-
p38 MAPK, JNK, p-JNK, c-Fos, NFATc1, and β-actin at a
concentration of 10 µg/mL were incubated at 4˚C for 4
hours. The secondary HRP-conjugated antibody was goat
anti-rabbit IgG, anti-mouse IgG (Stressgen Biotechnologies
Corporation, Victoria, Canada). Reactive proteins were
detected using enhanced chemiluminescence (Amersham
Life Sciences, Arlington, IL, USA) with Fuji Film LAS-
3000 (Fuji Film, Tokyo, Japan).
RNA isolation and reverse transcription-
polymerase chain reaction
Total RNA was extracted from cultured cells using
the TRIsol reagent (Invitrogen, Carlsbad, CA, USA) in
accordance with the manufacturer’s instructions. Aliquots
of 1 µg of RNA were reverse-transcribed using a Maxime
RT Premix Kit (iNtRON Biotechnology, Seongnam,
Korea). cDNA was amplified using the following primer
sets: c-Fos sense, 5’-ATCGGAGGAGGGAGCTGACA-3’; c-
Fos antisense, 5’-GGAACCGGACAGGTCCACAT-3’;
NFATc1 sense, 5’-TGTGCAGCCAATTCCCCTG-3’;
NFATc1 antisense, 5’-ATACCCCCCAGACCGCATC-3’;
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
sense, 5’-ACCACAGTCCATGCCATCAC-3’; GAPDH
antisense, 5’-TCCACCACCCTGTTGCTGTA-3’. PCR
products were electrophoresed on 1% agarose gels and
visualized by staining with ethidium bromide. Densitometric
analysis was performed on the relative intensity of each
band using the Multi Gauge program, version 3.0 (Fuji
Film). 
Cytochemical assessment of osteoclast formation
(tartrate-resistant acid phosphatase stain)
Cells were fixed with 3.7% formalin and permeabilized
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Figure 3. Dose-dependent inhibition of IL-1β-stimulated, RANKL-mediated TRAP (+) cell formation (A) and resorption area
formation (B) by EACT. Osteoclast precursors were cultured with M-CSF (30 ng/mL) and RANKL (50 ng/mL) in the presence or
absence of IL-1β (1.0 ng/mL) or EACT (50, 100 or 200 µg/mL). TRAP (+) cells containing five or more nuclei and area of resorption
pit were evaluated as multinucleated osteoclasts.
Error bars indicate the standard deviation of the mean (n = 3).
IL, interleukin; RANKL, receptor activator of NF-κB ligand; TRAP, tartrate-resistant acid phosphatase; EACT, ethyl acetate extract of
Cudrania tricuspidata; M-CSF, macrophage colony stimulating factor.
ap < 0.05.
bp < 0.01 vs. IL-1β without EACT.
A Bin 0.1% Triton X-100 for 10 minutes. The cells were stained
with tartrate-resistant acid phosphatase stain (TRAP)
solution using a leukocyte acid phosphatase kit (Sigma)
according to the manufacturer’s instructions. The numbers
of osteoclasts were expressed as total counts per 48-well
plate. Photographs were taken under a fluorescence
microscope.
Resorption assay
Bone marrow cells (3 × 104 cells/well) were added to 4-
well tissue culture plates coated with a calcium phosphate
thin film (OAAS plates, Oscotec, Cheonan, Korea) prepared
according to the manufacturer’s instructions. After 2
weeks in culture, the cells were brushed away and OAAS
plates were stained with toluidine blue. The area of resorption
pits was measured in four randomly selected areas of each
dentine slice using an image analysis system (Image Gauge,
Tokyo, Japan).
Statistical analysis
All data are expressed as the means ± SD of triplicate
measurements. Group mean values were compared by
Student’s t-test or analysis of variance as appropriate, and
p < 0.05 was taken to indicate statistical significance.
Statistical analyses were performed using SPSS version
12.0 (SPSS Inc., Chicago, IL, USA). 
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Figure 4. EACT inhibits IL-1β‚-stimulated, RANKL-mediated
survival of osteoclast precursors. The survival of bone marrow
cells was evaluated with a CCK-8 kit after culture for 3 days
with/without IL-1β (1.0 ng/mL) and EACT (100 µg/mL).
Error bars indicate the standard deviation of the mean (n = 3).
EACT, ethyl acetate extract of Cudrania tricuspidata; IL,
interleukin; RANKL, receptor activator of NF-κB ligand.
ap < 0.05 vs. no IL-1β and EACT.
bp < 0.05 vs. no IL-1β and EACT.
Figure 5. EACT suppresses IL-1β-stimulated, RANKL-mediated c-Fos and NFATc1 activation. To evaluate the expression of c-Fos and
NFATc1 mRNA and protein, we performed immunoblotting and RT-PCR. Bone marrow macrophages were prepared from bone
marrow cells and cultured for 12 hr or 24 hr with M-CSF (30 ng/mL) and RANKL (50 ng/mL) in the presence or absence of IL-1β (1.0
ng/mL) or EACT (100 µg/mL). Total RNA was extracted and analyzed by RT-PCR. The cells were also lysed, and the lysates were
immunoblotting. IL-1β enhanced the expression of c-Fos and NFATc1 mRNA and protein compared with the results without IL-1β.
EACT inhibited the IL-1β-induced expression of c-Fos and NFATc1 mRNA and protein.
Error bars indicate the standard deviation of the mean (n = 3).
EACT, ethyl acetate extract of Cudrania tricuspidata; IL, interleukin; RANKL, receptor activator of NF-κB ligand; NFATc1, nuclear
factor of activated T-cells c1; RT-PCR, reverse transcription?polymerase chain reaction; M-CSF, macrophage colony stimulating factor.
ap < 0.05 vs. no IL-1β and EACT.
bp < 0.05 vs. no IL-1β and EACT.RESULTS
EACT inhibits RANKL-mediated or IL-1β β-stimulated
osteoclast differentiation
To determine the effects of EACT on RANKL-mediated
or IL-1β-stimulated osteoclastogenesis, we initially
measured the formation of TRAP (+) mononuclear cells as
an indicator of osteoclast differentiation, which satisfied
most of the morphological criteria of osteoclasts. IL-1β
significantly increased the formation of TRAP (+) cells
compared to the absence of this cytokine (550.6 ± 35.1 vs.
208.8 ± 20.3, respectively, p < 0.05). EACT significantly
decreased RANKL-mediated or IL-1β-stimulated formation
of TRAP (+) cells compared to the absence of EACT (84.7
± 8.3 vs. 274.3 ± 13.8, respectively, p < 0.05, Fig. 1A and
1B).
We also measured resorption area as another indicator
of osteoclast formation. IL-1β significantly increased
the resorption area compared to the absence of IL-1β
(39.5 ± 8.3 vs. 18.3 ± 4.8, respectively, p < 0.05). EACT
also significantly decreased the RANKL-mediated or IL-
1β-stimulated formation of resorption pits compared to
the absence of EACT (2.8 ± 0.8 vs. 21.5 ± 3.9, respectively,
p < 0.05; Fig. 2A and 2B). EACT inhibited the RANKL-
mediated or IL-1β-stimulated formation of TRAP (+) cells
and resorption pits in a dose-dependent manner (Fig. 3A
and 3B). These effects were also time dependent (data not
shown).
EACT inhibits RANKL-mediated or IL-1β β-stimulated
survival of osteoclast precursors
To evaluate the effects of EACT on the growth properties
of bone marrow cells from 5-week-old male ICR mice, we
measured cell survival with M-CSF (30 ng/mL) and
RANKL (50 ng/mL) in the presence or absence of EACT
(100 µg/mL) or IL-1β (1 ng/mL) for 3 days as described in
“METHODS.” As shown in Fig. 4, IL-1β significantly
increased the survival of osteoclast precursor cells compared
to controls without IL-1β(p< 0.05). EACT also significantly
inhibited the survival of osteoclast precursor cells compared
to IL-1β (p < 0.05). However, there was no difference in
survival of osteoclast precursor cells between controls and
cultures with EACT. To determine the dose-dependent
effects of EACT on IL-1β-induced survival of osteoclast
precursor cells, we added various doses of EACT to the
osteoclast precursor cell cultures with IL-1β (1.0 ng/mL)
for 3 days and performed a CCK-8 assay. The inhibitory
effects of EACT were significantly enhanced as the concen-
tration of EACT increased (data not shown).
EACT suppresses c-Fos and NFATc1 expression
induced by RANKL or IL-1β β
Osteoclast differentiation is regulated by the induction
of various genes in response to RANKL and other osteotropic
agents, including IL-1β and TNF-α. IL-1β is a very
important inflammatory cytokine in RA and causes bone
loss by increasing osteoclast formation. Both c-Fos and
NFATc1 play essential roles in the differentiation of
osteoclast precursors [7]. Therefore, we examined whether
EACT regulates the expression of c-Fos and NFATc1 in
response to RANKL or IL-1β. The densitometric value of
RT-PCR normalized by GAPDH intensity showed that
98 The Korean Journal of Internal Medicine Vol. 25, No. 1, March 2010
p-ERK 1/2
ERK 1/2
p-p38
p38
p-JNK
JNK
Figure 6. Effects of EACT on IL-1β-stimulated, RANKL-
mediated MAPK signal pathways. To evaluate the mechanism
of EACT on IL-1β-induced, RANKL-mediated osteoclast
differentiation, we evaluated MAPK signaling pathways (ERK,
p38, and JNK) by immunoblotting. Bone marrow macrophages
were cultured with M-CSF (30 ng/mL) and RANKL (50 ng/mL)
for 10 min in the presence or absence of IL-1β (1.0 ng/mL) or
EACT (100 µg/mL). IL-1β enhanced the phosphorylation of
ERK, p38, and JNK; EACT inhibited the IL-1β-stimulated,
RANKL-mediated activation of ERK 1/2 and p38.
Error bars indicate the standard deviation of the mean (n = 3).
EACT, ethyl acetate extract of Cudrania tricuspidata; IL,
interleukin; RANKL, receptor activator of NF-κB ligand; MAPK,
mitogen activated protein kinase; ERK, extracellular signal
regulated kinase; JNK, c-Jun amino-terminal kinase; M-CSF,
macrophage colony stimulating factor.
ap < 0.05 versus no IL-1β and EACT.
bp < 0.05 versus no IL-1β and EACT.
cp < 0.05 versus IL-1β without EACT.EACT significantly decreased the RANKL-mediated or
IL-1β-stimulated expression of c-Fos and NFATc1 mRNA
(Fig. 5A). Consistent with the results of the RT-PCR analyses,
expression of c-Fos and NFATc1 protein levels increased
in response to RANKL and IL-1β, but the expression of
both c-Fos and NFATc1 was significantly inhibited by EACT
(Fig. 5B). Thus, EACT may inhibit osteoclast differentiation
by inhibiting c-Fos and NFATc1 expression in response to
RANKL and IL-1β. 
EACT suppresses MAPKs signal pathways
induced by RANKL or IL-1β β
To determine the involvement of signal transduction and
the mechanisms underlying the effects of EACT on IL-1β-
stimulated RANKL-mediated osteoclast differentiation,
we evaluated the activation of MAPKs in bone marrow cells.
The densitometric values on immunoblots normalized
according to β-actin intensity showed that IL-1β activated
intracellular MAPKs, ERK 1/2, p38, and JNK (p < 0.05)
and EACT significantly inhibited IL-1β-induced activation
of intracellular MAPKs, including ERK and p38 (p < 0.05,
Fig. 6). However, the effects of IL-1β on NF-κB activation
were unaffected by EACT (data not shown). These results
indicated that EACT inhibits RANKL-mediated or IL-1β-
stimulated osteoclast differentiation via intracellular
MAPKs pathways.
DISCUSSION
The results of this study show that EACT inhibits IL-1β-
stimulated RANKL-mediated osteoclast differentiation in
a dose-dependent manner by inhibiting activation of the
ERK1/2 and p38 MAP kinases as well as inhibiting c-Fos
and NFATc1 expression. These findings suggest that
EACT plays an important role in inhibiting bone loss by
preventing osteoclast formation and that it may be useful
as a new therapeutic agent for managing osteoporosis or
bone destruction in inflammatory diseases such as RA.
CT is a deciduous tree distributed over South Korea,
China, and Japan, the cortex and root bark extract of are
used as traditional treatments for inflammation, gastritis,
and tumors [8]. However, there have been few studies of
the pharmacological activity of CT extract extract of
CT. Several reports have suggested various effects of CT
extract extract of CT, including antioxidant activity [9],
inhibitory effects on nitric oxide synthase [10], and
inhibitory effects on proliferation of tumor cells [12]. Yet
there have been few reports on the function and activity
of CT extract extract of CT in inflammatory reactions.
Chang et al. [11] reported that CT extract extract of CT
could inhibit the proliferation of antigen-mediated spleen
and T cells, which can accelerate inflammation and also
reduce production of the proinflammatory cytokines IL-2
and IFN-γ in antigen-mediated T cells. Although these
results suggest that CT extract extract of CT has effects on
immune-mediated inflammatory joint diseases, including
RA, the possible manner of osteoclast differentiation
by which CT EACT inhibits inflammation-associated bone
loss remains to be determined. There have been no studies
of the effects on bone loss of inflammatory stimuli, especially
IL-1, which plays a crucial role in the pathogenesis of bone
destruction in RA.
The most striking features of RA are the hyperplasia of
synovial fibroblasts in the lining layer and periarticular
bone loss, which lead to joint destruction [15,16]. IL-1 plays
an important role in the pathogenesis of inflammatory
synovitis and joint destruction in RA by inducing the
differentiation and activation of osteoclasts [17]. IL-1 can
recruit and activate TRAF via heterodimeric IL-1 receptors.
Thus, IL-1 differentiates and activates osteoclasts via
intracellular signaling pathways, including MAPKs, c-Fos,
and NFATc1 [18]. The results of the present study indicate
that osteoclast differentiation induced by IL-1 can be
significantly inhibited by EACT in a dose- and time-
dependent manner. Thus, EACT may be an ideal treatment
for bone loss in inflammatory arthritis.
There are more than 30 volatile components in EACT,
and 8 of these compounds have antiinflammatory effects
[11]. Further studies are needed to define which components
of EACT are responsible for the observed results. This
study shows that EACT inhibits the differentiation of
osteoclasts in media with stimulating factors and inhibits
IL-1-induced osteoclast differentiation. Further studies are
required to determine the effects of EACT on osteoclast
differentiation in the absence or presence of stimulating
factors and to define the precise mechanisms of these
effects.
A member of the TNF superfamily, RANKL mediates
multiple signaling pathways via RANK in osteoclast
precursors and activates critical transcription factors for
osteoclast differentiation and function [1,4]. NFATc1 is
one of the most important transcription factors and is
expressed in osteoclast precursors through Ca2+ oscillation,
MAPKs, and c-Fos or NF-κB in response to RANKL [19].
IL-1 differentiates and activates osteoclasts by recruiting
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including MAPKs, c-Fos, and NFATc1. We found that the
inhibition of osteoclast differentiation by EACT coincides
with the regulation of ERK 1/2, p38 MAPKs, c-Fos, and
NFATc1.
This is the first study to indicate that CT EACT inhibits
the IL-1β-stimulated RANKL-mediated differentiation of
osteoclasts. This study also shows that CT EACT inhibits
the phosphorylation of MAPK pathways and the activation
of c-Fos and NFATc1. Taken together, these findings
suggest that CT EACT may be useful for treating bone loss
in inflammatory diseases, including RA. However, further
studies are required to define the precise mechanism
underlying the inhibition of osteoclast differentiation and
to identify the active components in EACT.
Conflict of interest
No potential conflict of interest relevant to this article
was reported.
Acknowledgements
This study was supported by a Chung-Ram Research
Grant from the Korean Association of Internal Medicine
and a grant of the Korea Healthcare Technology R&D
Project, Ministry for Health, Welfare, and Family Affairs,
Republic of Korea (A084144).
REFERENCES
1.Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin
TJ. Modulation of osteoclast differentiation and function by the
new members of the tumor necrosis factor receptor and ligand
families. Endocr Rev 1999;20:345-357.
2. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL. Lipopolysaccharide-
stimulated osteoclastogenesis is mediated by tumor necrosis
factor via its P55 receptor. J Clin Invest 1997;100:1557-1565.
3. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs
BL. The roles of osteoprotegerin and osteoprotegerin ligand in the
paracrine regulation of bone resorption. J Bone Miner Res 2000;
15:2-12.
4.Lee ZH, Kim HH. Signal transduction by receptor activator of
nuclear factor kappa B in osteoclasts. Biochem Biophys Res
Commun 2003;305:211-214.
5.Teitelbaum SL, Ross FP. Genetic regulation of osteoclast
development and function. Nat Rev Genet 2003;4:638-649.
6. Matsuo K, Galson DL, Zhao C, et al. Nuclear factor of activated T-
cells (NFAT) rescues osteoclastogenesis in precursors lacking c-
Fos. J Biol Chem 2004;279:26475-26480.
7. Takayanagi H, Kim S, Koga T, et al. Induction and activation of
the transcription factor NFATc1 (NFAT2) integrate RANKL
signaling in terminal differentiation of osteoclasts. Dev Cell 2002;
3:889-901.
8.Lee IK, Kim CJ, Song KS, et al. Cytotoxic benzyl dihydroflavonols
from Cudrania tricuspidata. Phytochemistry 1996;41:213-216.
9. Cho EJ, Yokozawa T, Rhyu DY, Kim HY, Shibahara N, Park JC.
The inhibitory effects of 12 medicinal plants and their component
compounds on lipid peroxidation. Am J Chin Med 2003;31:907-
917.
10.Kang DG, Hur TY, Lee GM, et al. Effects of Cudrania tricuspidata
water extract on blood pressure and renal functions in NO-
dependent hypertension. Life Sci 2002;70:2599-2609.
11. Chang SH, Jung EJ, Lim DG, et al. Anti-inflammatory action of
Cudrania tricuspidata on spleen cell and T lymphocyte proliferation.
J Pharm Pharmacol 2008;60:1221-1226.
12. Seo WG, Pae HO, Oh GS, et al. Ethyl acetate extract of the stem
bark of Cudrania tricuspidata induces apoptosis in human
leukemia HL-60 cells. Am J Chin Med 2001;29:313-320.
13. Park HJ, Park OJ, Shin J. Receptor activator of NF-kappaB ligand
enhances the activity of macrophages as antigen presenting cells.
Exp Mol Med 2005;37:524-532.
14.Nakagawa T, Takahashi M, Ozaki T, et al. Autoinhibitory
regulation of p73 by Delta Np73 to modulate cell survival and
death through a p73-specific target element within the Delta
Np73 promoter. Mol Cell Biol 2002;22:2575-2585.
15. Cawston TE. Proteinases and connective tissue breakdown. In:
Henderson B, Edwards JCW, Pettipher ER, eds. Mechanisms and
Models in Rheumatoid Arthritis. London: Academic Press,
1995:333-359.
16.Han MK, Kim JS, Park BH, et al. NF-kappaB-dependent
lymphocyte hyperadhesiveness to synovial fibroblasts by hypoxia
and reoxygenation: potential role in rheumatoid arthritis. J
Leukoc Biol 2003;73:525-529. 
17. Gitter BD, Labus JM, Lees SL, Scheetz ME. Characteristics of
human synovial fibroblast activation by IL-1 beta and TNF alpha.
Immunology 1989;66:196-200.
18. Gravallese EM, Galson DL, Goldring SR, Auron PE. The role of
TNF-receptor family members and other TRAF-dependent
receptors in bone resorption. Arthritis Res 2001;3:6-12.
19. Takayanagi H. Mechanistic insight into osteoclast differentiation
in osteoimmunology. J Mol Med 2005;83:170-179. 
100 The Korean Journal of Internal Medicine Vol. 25, No. 1, March 2010